303 related articles for article (PubMed ID: 32797475)
1. The effect of thyroid hormone status on selected antioxidant parameters in patients with Graves' disease and active thyroid-associated orbitopathy.
Londzin-Olesik M; Kos-Kudła B; Nowak A; Wielkoszyński T; Nowak M
Endokrynol Pol; 2020; 71(5):418-424. PubMed ID: 32797475
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.
Sieminska L; Niedziolka D; Pillich A; Kos-Kudla B; Marek B; Nowak M; Borgiel-Marek H
J Endocrinol Invest; 2008 Sep; 31(9):745-9. PubMed ID: 18997483
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves' Disease with Active Thyroid-Associated Orbitopathy.
Londzin-Olesik M; Kos-Kudla B; Karpe J; Nowak A; Nowak M
Exp Clin Endocrinol Diabetes; 2021 Oct; 129(10):762-769. PubMed ID: 33157557
[TBL] [Abstract][Full Text] [Related]
4. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
Bednarek J; Wysocki H; Sowiński J
Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
[TBL] [Abstract][Full Text] [Related]
5. [Concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients witt Graves' disease and thyroid associated orbitopathy].
Kulig G; Pilarska K; Kulig J
Przegl Lek; 2004; 61(12):1319-24. PubMed ID: 15850321
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
7. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
8. Effects of experimentally induced maternal hypothyroidism and hyperthyroidism on the development of rat offspring: II-the developmental pattern of neurons in relation to oxidative stress and antioxidant defense system.
Ahmed OM; Ahmed RG; El-Gareib AW; El-Bakry AM; Abd El-Tawab SM
Int J Dev Neurosci; 2012 Oct; 30(6):517-37. PubMed ID: 22664656
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine therapy and Graves' disease - Myths and reality.
Plazinska MT; Sawicka-Gutaj N; Czarnywojtek A; Wolinski K; Kobylecka M; Karlińska M; Prasek K; Zgorzalewicz-Stachowiak M; Borowska M; Gut P; Ruchala M; Krolicki L
PLoS One; 2020; 15(1):e0226495. PubMed ID: 31929534
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study.
Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M
Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926
[TBL] [Abstract][Full Text] [Related]
12. Oxidation products and antioxidant markers in plasma of patients with Graves' disease and toxic multinodular goiter: effect of methimazole treatment.
Bednarek J; Wysocki H; Sowinski J
Free Radic Res; 2004 Jun; 38(6):659-64. PubMed ID: 15346657
[TBL] [Abstract][Full Text] [Related]
13. Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves' ophthalmopathy.
Akarsu E; Buyukhatipoglu H; Aktaran S; Kurtul N
Clin Endocrinol (Oxf); 2011 Jan; 74(1):118-24. PubMed ID: 21044110
[TBL] [Abstract][Full Text] [Related]
14. Decreased serum level of IL-7 in patients with active Graves' disease.
Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
[TBL] [Abstract][Full Text] [Related]
15. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
16. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
Kashiwai T; Tada H; Watanabe Y; Shimaoka Y; Yagoro A; Hidaka Y; Fujikado T; Amino N
Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
[TBL] [Abstract][Full Text] [Related]
17. Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease.
Sewerynek J; Wiktorska J; Nowak D; Lewinski A
Endocr Regul; 2000 Jun; 34(2):83-9. PubMed ID: 10911409
[TBL] [Abstract][Full Text] [Related]
18. Unusual onset of thyroid associated orbitopathy during pregnancy: case report and review of literature.
Aranyosi JK; Deli T; Erdei A; Toth G; Jakab A; Fodor M; Nagy EV; Ujhelyi B
BMC Endocr Disord; 2020 Dec; 20(1):183. PubMed ID: 33317492
[TBL] [Abstract][Full Text] [Related]
19. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy.
Komosinska-Vassev K; Olczyk K; Kucharz EJ; Marcisz C; Winsz-Szczotka K; Kotulska A
Clin Chim Acta; 2000 Oct; 300(1-2):107-17. PubMed ID: 10958867
[TBL] [Abstract][Full Text] [Related]
20. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
